Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   UROLOGY JOURNAL   March-April 2019 , Volume 16 , Number 2; Page(s) 157 To 161.
 
Paper: 

Effect of Hormonal Therapy for Volume Reduction, Lower Urinary Tract Symptom Relief and Voiding Symptoms in Prostate Cancer: Leuprolide vs Goserelin

 
DOI: 

10.22037/uj.v0i0.4245

 
Author(s):  Yikilmaz Taha Numan*, ozturk Erdem, Hizli Fatih, Hamidi Nurullah, Basar Halil
 
* Department of Urology, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Yenimahalle, Ankara 06200, Turkey
 
Abstract: 
Purpose: The complaints of lower urinary tract symptoms in cases with prostate carcinoma (Pca) are associated with coexisting benign prostate hyperplasia or aging bladder. The aim of this study was to investigate and compare the effect of goserelin acetate with leuprolide acetate on total prostate volume (TPV), post voiding residue (PVR), International Prostate Symptom Score (IPSS) and maximum flow rate (Qmax) reduction in cases of advanced Pca. Materials and Methods: The study initially enrolled 71 patients who presented at our clinic for hormonotherapy because of advanced prostate carcinoma between May 2015 and August 2016. A total of 51 patients were found suitable for the study and were divided into two groups as Group 1 who received goserelin acetate (10. 8 mg /3 months) and Group 2 who received leuprolide acetate (22. 5 mg /3 months). Age, Gleason score, T stage, pre and post treatment Prostate specific antigen (PSA) and testesterone level, TPV, IPSS, PVR, and Qmax values were recorded retrospectively. Changes in parameters were assessed every 3 months. Results: Analysis was made on 51 patients in this study. No statistically significant difference was determined between the two groups in respect of the mean percentage decrease in PSA (98. 7% and 98. 4%, respectively; P =. 9) and testosterone (92. 9 % and 96. 4 %, respectively; P =. 15) from baseline to 6 months but TPV reduced by-20. 2 % ± 4. 8 and-15. 6 % ± 1. 04, the median total IPSS score decreased by-34. 77 % ± 8. 8 and-19. 77 % ± 6. 1, median Qmax increased by 45. 34 % ± 10. 16 and 23. 21 % ± 6. 93, and median PVR decreased by-31. 54 % ± 8. 4 and-19. 23 % ± 5. 5, respectively for the two groups (all parameters P <. 05) Conclusion: In this study, the improvement observed in voiding parameters with the use of goserelin acetate was better than with leuprolide acetate. The superiority of the goserelin acetate group was determined in particular on the reduction of TPV, PVR and IPSS. Although the PSA follow-up time was short, no significant difference was determined between the groups in the early oncological outcomes.
 
Keyword(s): androgen deprivation therapy,total prostate volume,post voiding residue,voiding symptoms,prostate carcinoma
 
 
References: 
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

Yikilmaz, T., & ozturk, E., & Hizli, F., & Hamidi, N., & Basar, H. (2019). Effect of Hormonal Therapy for Volume Reduction, Lower Urinary Tract Symptom Relief and Voiding Symptoms in Prostate Cancer: Leuprolide vs Goserelin. UROLOGY JOURNAL, 16(2), 157-161. https://www.sid.ir/en/journal/ViewPaper.aspx?id=665743



Vancouver: Copy

Yikilmaz Taha Numan, ozturk Erdem, Hizli Fatih, Hamidi Nurullah, Basar Halil. Effect of Hormonal Therapy for Volume Reduction, Lower Urinary Tract Symptom Relief and Voiding Symptoms in Prostate Cancer: Leuprolide vs Goserelin. UROLOGY JOURNAL. 2019 [cited 2021July24];16(2):157-161. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=665743



IEEE: Copy

Yikilmaz, T., ozturk, E., Hizli, F., Hamidi, N., Basar, H., 2019. Effect of Hormonal Therapy for Volume Reduction, Lower Urinary Tract Symptom Relief and Voiding Symptoms in Prostate Cancer: Leuprolide vs Goserelin. UROLOGY JOURNAL, [online] 16(2), pp.157-161. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=665743.



 
  pdf-File
Yearly Visit 37
 
 
Latest on Blog
Enter SID Blog